Fate Therapeutics, Inc.

FATE • Biotechnology

Movimiento fuerte

FATE+10.75%

vs. cierre anterior $1.86

$2.06

▲ +0.20 (+10.75%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$248.02M

Crecimiento

-5.9%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.38Liquidez saludable · 5.79Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:15 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$2.06

Change10.75%

Shares Out120.40M

Market Cap$248.02M

Enterprise Value$94.25M

52W Range0.93 - 3.23

Beta2.53

P/E-1.97

P/S38.21

P/B1.62

P/FCF-2.35

EV/Sales14.52

Price$2.06

Change10.75%

Shares Out120.40M

Market Cap$248.02M

Enterprise Value$94.25M

52W Range0.93 - 3.23

Beta2.53

P/E-1.97

P/S38.21

P/B1.62

P/FCF-2.35

EV/Sales14.52

EV/EBITDA-0.77

EV/FCF-0.89

Earnings Yield-50.80%

FCF Yield-42.60%

Dividend Yield0.00%

Gross Margin-94.12%

Oper. Margin-22.22%

Profit Margin-20.51%

Debt/Eq0.38

Current Ratio5.79

Quick Ratio5.79

Revenue 5Y-5.94%

Target$5.63

Target Upside173.30%

Target Median$5.50

Target Range3.50 - 8.00

Volume2.35M

Avg Volume3.37M

EPS Surprise0.03

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

75/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

58/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.38Liquidez saludable · 5.79Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

FATE

Analyst sentiment

Based on 31 analyst votes · 2026-10-21

73/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-14

Bajo

$4.00

Promedio

$5.50

Mediana

$5.50

Alto

$7.00

Resumen de la compañía

IPO: 10/1/2013

Industria: Biotechnology

P/B i: 1.62

Deuda / Patrimonio i: 0.38

Margen operativo: -2222.45%

Margen neto: -2051.08%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.38

Ratio corriente: 5.79

Ratio rápido: 5.79

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 1 venta interna de alto volumen detectada

Valamehr Bahram

Transacción: 08/04/2026

VENTA

Cambio

-43,947

Precio

$2.46

Presentación

08/05/2026

Tipo

VENTA

TAHL CINDY

Transacción: 08/04/2026

VENTA

Cambio

-38,800

Precio

$2.46

Presentación

08/05/2026

Tipo

VENTA

Hamill Laura

Transacción: 06/12/2026

OTRO

Cambio

Precio

Not reported

Presentación

06/15/2026

Tipo

OTRO

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Valamehr Bahram	VENTA	-43,947	$2.46	08/04/2026	08/05/2026
TAHL CINDY	VENTA	-38,800	$2.46	08/04/2026	08/05/2026
Hamill Laura	OTRO	0	Not reported	06/12/2026	06/15/2026
Hamill Laura	COMPRA	+175,800	$2.06	06/12/2026	06/15/2026
RASTETTER WILLIAM H	COMPRA	+87,900	$2.06	06/12/2026	06/15/2026
ABERNETHY MATT	COMPRA	+87,900	$2.06	06/12/2026	06/15/2026
Agarwal Shefali	COMPRA	+87,900	$2.06	06/12/2026	06/15/2026
EPSTEIN ROBERT S	COMPRA	+87,900	$2.06	06/12/2026	06/15/2026
Jooss Karin	COMPRA	+87,900	$2.06	06/12/2026	06/15/2026
Xu Yuan	COMPRA	+87,900	$2.06	06/12/2026	06/15/2026
Lee Michael Stewart	COMPRA	+87,900	$2.06	06/12/2026	06/15/2026
Redmile Group, LLC	COMPRA	+87,900	$2.06	06/12/2026	06/15/2026
Valamehr Bahram	VENTA	-28,946	$1.88	05/20/2026	05/21/2026
TAHL CINDY	VENTA	-25,590	$1.88	05/20/2026	05/21/2026
TAHL CINDY	VENTA	-122,220	$1.32	05/06/2026	05/07/2026
TAHL CINDY	COMPRA	+122,220	$1.32	05/06/2026	05/07/2026
RASTETTER WILLIAM H	COMPRA	+25,000	$1.69	05/05/2026	05/06/2026
RASTETTER WILLIAM H	COMPRA	+25,000	$1.69	05/05/2026	05/06/2026
EPSTEIN ROBERT S	COMPRA	+25,000	$1.69	05/05/2026	05/06/2026
EPSTEIN ROBERT S	COMPRA	+25,000	$1.69	05/05/2026	05/06/2026

Sobre la compañía

Fate Therapeutics, Inc.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.

Fuente - Link

Competidores

ABOS ALEC CRBP INO MOLN NKTX PEPG PRLD SAVA VOR

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 62,900 shares of the Company's common stock at an exercise price per share of $2.30, which was the closing price per share of the Company's common stock as reported by NASDAQ on October 1, 2026, and (ii) restricted stock units (RSUs) representing 72,700 shares of its common stock to two newly-hired non-executive employees, including the newly-hired employee receiving the non-qualified stock options referenced above. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.

GlobeNewsWire

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the fourth quarter of 2026.

GlobeNewsWire

CIRM backs Fate’s FT819 lupus trial

What happened Fate Therapeutics, Inc. (NASDAQ: FATE) said the California Institute for Regenerative Medicine awarded it a $15.0 million CLIN2 grant on September 25, 2026. The grant supports RECLAIM-LN, a Phase 2, potentially registrational trial of FT819 in refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis. RECLAIM-LN, also called FT819-201, is a multicenter, open-label, single-arm

Defense World

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis

GlobeNewsWire

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at the American College of Rheumatology (ACR) Convergence 2026, being held November 6-11 in Orlando, Florida.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	-0.29	-0.26	0.03
2026-02-26	-0.27	-0.27	0
2025-11-13	-0.29	-0.27	0.02
2025-08-12	-0.35	-0.29	0.06
2025-05-13	-0.39	-0.32	0.07
2025-03-05	-0.44	-0.31	0.13
2024-11-12	-0.42	-0.4	0.02
2024-08-13	-0.47	-0.33	0.14
2024-05-09	-0.47	-0.47	0
2024-02-26	-0.57	-0.45	0.12
2023-11-08	-0.59	-0.46	0.13
2023-08-08	-0.58	-0.54	0.04